Healthcare / BiotechnologyNasdaqGS
$19.67
-0.04 (-0.20%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-27.5M · quality 67.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$1.7B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-16.6%
↓Gross Margin
N/A
•Debt/Equity
0.17
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2020–2025 · 5 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
-22.2%
FCF / Net income
0.71x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $123.7M · net income $-38.6M · FCF $-27.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | $123.7M | $123.7M | $75.6M | — | — | — | — |
| Net Income | $-38.6M | $-38.6M | $-72.7M | $-135.4M | $-108.5M | $-74.0M | $-35.9M |
| EBITDA | $-45.9M | $-45.9M | $-73.0M | $-137.1M | $-108.6M | — | — |
| EPS | — | — | -1.18 | -2.63 | -2.30 | — | — |
| Operating Margin | -43.8% | -43.8% | -107.3% | — | — | — | — |
| Net Margin | -31.2% | -31.2% | -96.1% | — | — | — | — |
| Balance Sheet | |||||||
| Debt/Equity | 0.17 | 0.17 | 0.19 | 0.26 | 0.17 | — | — |
| Current Ratio | 9.54 | 9.54 | — | — | — | — | — |
| Cash Flow | |||||||
| Free Cash Flow | $-27.5M | $-27.5M | $38.0M | $-62.8M | $-105.4M | $-69.1M | $-26.4M |
| Returns | |||||||
| ROE | -16.6% | -16.6% | -32.6% | -75.5% | -40.0% | -21.3% | 73.6% |
| Valuation | |||||||
| P/B | 5.53 | 5.53 | 1.98 | 1.58 | 1.39 | — | — |
| Growth & Yield | |||||||
| Revenue Growth | 63.5% | 63.5% | — | — | — | — | — |
| EPS Growth | — | — | 55.1% | -14.3% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+370.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.18 → n/d
Residual
+370.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.